Our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those with cancer begins with a very considered step forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of Purpose®.
In that time, we have designed, developed and delivered treatments that change what it means to have, and to treat, cancer. We have years of outstanding legacy in haematological malignancies and prostate cancer. In fact, we are behind nine licensed oncology treatments in Europe and over a million patients have been treated with these medicines worldwide.
We recognise that every cancer is different, each possessing unique challenges along the way. But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference.
CAR-T cell therapy is a specialised and individual treatment involving multiple processes and stakeholders. Explore this virtual reality CAR-T centre to learn about the different aspects of CAR-T cell therapy processes.
Worldwide in 2020 there were an estimated 19.3 million new cancer cases and 9.9 million deaths. Cancer brings devastation. Patients, their families, and the entire oncology community deserve meaningful change. At Janssen Oncology, we consistently integrate their perspectives into everything we do. But we don’t just listen, we use insight to create solutions that make a truly meaningful difference.
To help us achieve this we are privileged to have the support and participation of internationally renowned experts who form our scientific committee and faculties. Their involvement ensures we continue to provide clinically relevant and balanced education.
EGFR, epidermal growth factor receptor. FGFR, fibroblast growth factor receptor. NSCLC, non-small cell lung cancer.